Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.96 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20240418 | 0.89 | SMN1; SMN2 (0.80) | POLBGAASMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL2927161 | 0.78 | POLB (0.64) | POLBSMN1; SMN2SIGMAR1ALDH1A1TSHR | |
| SCHEMBL2933630 | 0.76 | SIGMAR1 (0.63) | POLBGAASMN1; SMN2SIGMAR1TSHR | |
| SCHEMBL10742934 | 0.75 | SMN1; SMN2 (0.57) | POLBSMN1; SMN2SIGMAR1ALDH1A1PKM | |
| SCHEMBL10745563 | 0.74 | SMN1; SMN2 (0.58) | POLBSMN1; SMN2SIGMAR1ALDH1A1PKM | |
| SCHEMBL20248789 | 0.74 | TSHR (0.57) | POLBSMN1; SMN2SIGMAR1ALDH1A1PKM | |
| SCHEMBL20248787 | 0.73 | SIGMAR1 (0.59) | POLBSMN1; SMN2SIGMAR1ALDH1A1MAPT | |
| SCHEMBL20248785 | 0.72 | SIGMAR1 (0.59) | POLBSMN1; SMN2SIGMAR1ALDH1A1PKM | |
| SCHEMBL270734 | 0.72 | SIGMAR1 (1.00) | POLBGAASMN1; SMN2SIGMAR1PKM | |
| SCHEMBL741341 | 0.71 | POLB (0.56) | POLBGAASMN1; SMN2SIGMAR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161310-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Teleos Therapeutics, LLC | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161310-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | GRIN1, GRIN2A, GRIN2C | POLB 4557/4885GAA 1414/4885SMN1; SMN2 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.